Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Trust our know-how, Fisons tells City

Article Abstract:

Fisons is seeking to fight off a bid by Rhone-Poulenc Rorer. Fisons pre-tax profit rose by by an estimated 8% to some 33 million pounds sterling for 1st half 1995, according to a forecast by Merill Lynch. The company's defense against the takeover bid emphasises its technology, especially gas propellants without CFC and its Ultrainhaler device for treating asthma. Analysts argue that profits are unlikely to be boosted for some three years by the Ultrainhaler.

Author: Ahmad, Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Rhone-Poulenc Rorer Inc., RPR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The breathless battle for Fisons

Article Abstract:

Rhone-Poulenc Rorer (RPR) is seeking to acquire Fisons, which argues that RPR is undervaluing the company. RPR stresses the potential of a new inhaler, and the importance of its earnings recovery. Fisons' profit is forecast to rise to 150 million pounds syerling for 1996 from 100 million pounds sterling. Other drugs companies could bid for Fisons, and they include Glaxo, Astra, Schering-Plough and Zeneca. RPR is likely to increase its offer for Fisons.

Author: Ahmad, Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Pharmaceutical Preparation Manufacturing, Proprietary Asthma Relief Preps, Antiasthmatic agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Company doctor acts fast to heal Fisons

Article Abstract:

Fisons has sold its research operations to Astra and is negotiating a merger with Medeva. The company is also selling its scientific instruments division to a US firm. Fisons was seen as a possible target for a takeover. Medeva has a strong presence in the US while Fisons is stronger in Europe, Fisons' marketing division is strong while Medeva has skills in selecting drugs. Fisons needs new products to market, and a merger would bring mutual benefits.

Author: Milner, Richard
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Medeva PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Mergers, acquisitions and divestments, Drugs, Fisons PLC
Similar abstracts:
  • Abstracts: The great pensions robbery. ISAs: The great leap forward? End of a relaxed regime
  • Abstracts: We do like to be beside the seaside. Catch me if you can. Back from hell
  • Abstracts: Keeping tabs on trust performance. Going global in the search for returns. Murky waters lie offshore
  • Abstracts: The right to choose. The principles of put and call
  • Abstracts: UK housing: policy options. The year that wasn't. Overseas funds buoy up UK market
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.